Company Overview and News
TC PipeLines (TCP) stock has fallen 37% so far in 2018. It tumbled in March, following an FERC (Federal Energy Regulatory Commission) policy revision that disallowed income tax allowance cost recoveries for FERC-regulated interstate MLP pipeline rates. Enbridge Energy Partners (EEP), Spectra Energy Partners (SEP), and Dominion Energy Midstream Partners (DM) fell 26%, 16%, and 51%, respectively, in that period.
Of the analysts surveyed by Reuters, 17% have rated TC PipeLines (TCP) a “buy.” About 58% have rated it a “hold,” and 25% have rated it a “sell.” The mean price target for TC PipeLines is $41.75. The stock is currently trading at $34. If TC PipeLines attains its mean price target in a year, it will be a price return of 23%.
While most income investors are reaching for big yields right now, a small group of “hidden yield” stocks are quietly handing smart investors growing income streams plus annual returns of 12%, 27.1% and even 54% or more per year.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
So far in this series, we have discussed the performance of the broader MLP sector, the top MLP gainers, and the top MLP losers in the week ending April 13, 2018. In this part, we’ll discuss the MLP rating updates last week.
MLPs and midstream stocks have been decimated in recent years due to a perfect storm of negative factors, including: the oil crash, rising interest rates, and a market correction.
MLPs have been hammered in recent years by a perfect storm of negative factors, including the oil crash, rising interest rates, a market correction, and a FERC tax rule change.
Tallgrass Energy Partners (TEP) and its GP (general partner), Tallgrass Energy GP (TEGP), were the top MLP gainers last week, which ended March 30, 2018. TEGP and TEP rose 7.9% and 7.6%, respectively, last week. The Tallgrass duo rallied after Tallgrass Energy GP announced the acquisition of Tallgrass Energy Partners in an all-stock deal.
Midstream firms, Dominion, Sanchez, & Energy Transfer topped February's broker-vetted Energy Sector gains list, while Awilco Drilling, was tops by yield, as calculated 3/28/18.
Interstate pipeline MLPs continued to be among the worst performers in the week ending March 23 due to downward price revisions from various Wall Street analysts. Dominion Midstream Energy Partners (DM) and Spectra Energy Partners (SEP) were among the top three MLPs losses last week. They fell 24.8% and 10.8% last week.
Shares of Spectra Energy Partners (SEP) have undergone some wild swings over the last week or so and implied volatility has spiked as a result. Shares are now trading at just over $32 a share and look very attractive at these levels. We have been long Spectra for a while but may double down here due to the lower risk model Spectra enjoys compared to other master limited partnerships. The sharp drop in the shares recently has spiked the dividend yield to a whopping 8.
MLP investors have certainly seen their conviction tested of late. Poor stock performance was recently compounded by the Federal Energy Regulatory Commission’s (FERC) ruling on cost of service contracts earlier this month. Although MLPs don’t pay tax, interstate natural gas pipeline tariffs based on cost-of-service have historically included an allowance for taxes paid by their investors. Following a court challenge by United Airlines, FERC has now disallowed this practice.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET